Tech: Hydrix reckons a maiden profit is on the way… 18 years after listing
Hydrix (ASX:HYD) is forecasting “record” revenue of $4.3m in the June quarter and its first ever profit of sorts.
This quarter the company expects to deliver a maiden cash operating profit of around $400,000 and full year revenue around $13.25m.
The stock itself has surged nearly 35 per cent to 3.1c.
But it has a long way to go to prove that this time, it’s different.
The stock is no stranger to one-off share price spikes on the back of good news: it’s happened almost every year since 2013 but never resulted in a long term upswing.
It never managed to get that out of development and switched into MEMS (micro-electrical mechanical systems chips) in 2013, which led to an initial share price jump before a massive surge in 2014.
But it also struggled to get that very complicated chip technology off the ground.
Panorama bought Hydrix in late 2017, a company which is the “everything” to specialist tech design needs, from medtech to defence critical systems.
Now they’re anticipating that the new-look business can reverse the latest six-year trend of falling share prices.
“The company has now reported five consecutive quarters of quarterly revenue growth, which is testament to the strength of our business,” said Hydrix CEO Peter Lewis.
“We expect to exceed all of our second half milestones, which provide solid momentum leading into FY20”.
Ouch, those downgrades can be painful: Sensera (ASX:SE1) just admitted it’s going to miss its full year revenue forecast by about $US300,000 ($430,042).
The figures it’s now expecting are $US10.5m to $US11m thanks to an order that slipped into July.
Speedcast (ASX:SDA) also had to eat humble pie, saying it expected underlying EBITDA (earnings before interest, tax, depreciation and amortisation) will be down about 12 per cent, to $US140m-$US150m.
It had been expecting $US160m-$US171m.
It blamed a raft of reasons from NBN delays, customer churn in one industry, technical problems with a big contract, and social unrest in Mozambique.
Needless to say the stock is down — 38 per cent to $2.16.
But cheer up: Dotz Nano (ASX:DTZ), fresh out of a revamp with new contracts, reckons it’s solved brain cancer.
A mouse study of its graphene nano-dots at Rice University in the US, currently used for anti-counterfeiting, suggests they can scavenge oxidised particles in the body — free radicals — and therefore help to treat or prevent brain injuries, cancers, strokes, MS and heart attacks.
Reffind (ASX:RFN) has rejected an invalid motion to get rid of chairman David Jackson. The notice was issued in late June.
Investors originally jumped into Reffind on the back of a blockchain loyalty deal with US company Loyyal and gamified employee experience tech WooBoard.
But a series of missteps meant the technology wasn’t advanced as fast as promised and the company ran short of money. An exodus of staff and directors topped that off.
Admin costs now account for half of the company’s spending and almost a third of its dwindling cash reserves.